Research programme: breast cancer vaccines - BioLife Science

Drug Profile

Research programme: breast cancer vaccines - BioLife Science

Alternative Names: HerVac; MimoVac

Latest Information Update: 31 Dec 2013

Price : $50

At a glance

  • Originator BioLife Science
  • Class Cancer vaccines
  • Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 31 Dec 2013 Discontinued - Preclinical for Breast cancer in Austria (Injection)
  • 03 May 2007 No development reported - Preclinical for Breast cancer in Austria (Injection)
  • 03 Feb 2005 Preclinical trials in Breast cancer in Austria (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top